



(12) **United States Patent**
Kikuchi et al.

(10) **Patent No.:** **US 9,125,939 B2**
(45) **Date of Patent:** **Sep. 8, 2015**

(54) **CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS**

(75) Inventors: **Tetsuro Kikuchi**, Tokushima (JP); **Taro Iwamoto**, Princeton, NJ (US); **Tsuyoshi Hirose**, Tokushima (JP)

(73) Assignee: **Otsuka Pharmaceutical Co., Ltd.**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 800 days.

(21) Appl. No.: **10/556,600**

(22) PCT Filed: **May 19, 2004**

(86) PCT No.: **PCT/US2004/013308**

§ 371 (c)(1),
(2), (4) Date: **Aug. 2, 2006**

(87) PCT Pub. No.: **WO2004/105682**

PCT Pub. Date: **Dec. 9, 2004**

(65) **Prior Publication Data**

US 2007/0031513 A1 Feb. 8, 2007

Related U.S. Application Data

(60) Provisional application No. 60/473,378, filed on May 23, 2003.

(51) **Int. Cl.**

A61K 31/47 (2006.01)
A61K 31/44 (2006.01)
A61K 33/14 (2006.01)
A01N 59/08 (2006.01)
A61K 45/06 (2006.01)
A61K 31/19 (2006.01)
A61K 31/195 (2006.01)
A61K 31/425 (2006.01)
A61K 31/4704 (2006.01)
A61K 31/496 (2006.01)
A61K 31/497 (2006.01)
A61K 31/55 (2006.01)
A61K 31/7008 (2006.01)
A61K 33/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 45/06** (2013.01); **A61K 31/19** (2013.01); **A61K 31/195** (2013.01); **A61K 31/425** (2013.01); **A61K 31/4704** (2013.01); **A61K 31/496** (2013.01); **A61K 31/497** (2013.01); **A61K 31/55** (2013.01); **A61K 31/7008** (2013.01); **A61K 33/00** (2013.01); **A61K 33/14** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 31/4704**; **A61K 31/496**; **A61K 31/497**; **A61K 33/00**; **A61K 33/44**; **A61K 2300/00**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,006,528 A 4/1991 Oshiro et al.
2001/0023254 A1 9/2001 McElroy
2002/0173513 A1 11/2002 Jordan et al.
2003/0027817 A1 2/2003 Tollefson
2003/0109546 A1 6/2003 Fenton
2005/0004106 A1 1/2005 Romano

FOREIGN PATENT DOCUMENTS

EP 0367141 A2 9/1990
EP 0966967 A2 12/1999
WO 97/35584 A1 10/1997
WO 99/62522 A1 12/1999
WO 00/59489 A2 10/2000
WO 02/060423 A2 8/2002
WO 02/087590 A1 11/2002
WO 03/026659 4/2003
WO 03/066039 A1 8/2003
WO 2004060374 A1 7/2004
WO 2004/100992 A2 11/2004

OTHER PUBLICATIONS

CN138-00ST, Apr. 2003.*

RU Search Report dated Nov. 8, 2006 issued in Patent Application No. 2004 009073.

Borwin Bandelow and Andreas Meier; Aripiprazole, a "Dopamine-Serotonin System Stabilizer" in the Treatment of Psychosis; German Journal of Psychiatry, vol. 6, No. 1, 2003; pp. 9-16.

Melissa P. Delbello, M. D., et al.; A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania; Journal of the American Academy of Child and Adolescent Psychiatry, vol. 41, No. 10, 2002, pp. 1216-1223.

Mauricio Tohen, M.D. et al.; Efficacy of Olanzapine in Combination with Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy; Archives of General Psychiatry, vol. 59, No. 1, 2002, pp. 62-69.

Frank I. Tarazi, et al., Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions; Psychopharmacology, vol. 161, No. 3, 2002, pp. 263-270.

(Continued)

Primary Examiner — Shobha Kantamneni

(74) *Attorney, Agent, or Firm* — Finnegan, Henderson, Farabow, Garrett & Dunner LLP

(57) **ABSTRACT**

The pharmaceutical composition of the present invention comprises a carbostyryl derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyryl derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazepine, oxcarbamazepine, zonisamide, lamotrigine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyryl derivative and a mood stabilizer to a patient with a mood disorder.

(56)

References Cited**OTHER PUBLICATIONS**

Merck Index 13, the Merck & Co. NJ. USA document, No. 791, 1788, 5368, 9625, 4342 and 2413, year 2001.

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 791, 2001 (year).

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 1788, 2001 (year).

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 5368, 2001 (year).

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 9625, 2001 (year).

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 4342, 2001 (year).

The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Thirteenth Edition, Merck Index & Co., NJ, USA document, No. 2413, 2001 (year).

Gordon et al., Mood Stabilization and weight loss with Topiramate, American Journal of Psychiatry, Jun. 1999, vol. 156, No. 6, pp. 968-969, see pp. 1 and 2.

Baldessarini et al, Hospital Use of Antipsychotic Agents in 1989 and 1993: Stable Dosing with Decreased Length of Stay, American Journal of Psychiatry, Jul. 1995, vol. 152, No. 7, pp. 1038-1044, see pp. 1-8.

Jacobsen et al., Risperidone in the Treatment of Affective Illness and Obsessive-Compulsive Disorder, Journal of Clinical Psychiatry, Sep. 1995, vol. 56, No. 9, pp. 423-429.

Weisler et al., Adjunctive Use of Olanzapine in Mood Disorders: Five Case Reports, Annals of Clinical Psychiatry, 1997, vol. 9, No. 4, pp. 259-262.

Mcelroy et al., Clozapine in the Treatment of Psychotic Mood Disorders, Schizoaffective Disorder, and Schizophrenia, J. Clin. Psychiatry, Oct. 1991, vol. 52, No. 10, pp. 411-414.

Citrome et al., Pharmacokinetics and Safety of Aripiprazole and Concomitant Mood Stabilizers, 2002, vol. 5, Suppl. 1, p. S187 (P4.E. 035).

Moeller et al., Treatment of Bipolar Disorder, J. Clin. Psychiatry, 2003, vol. 64, Suppl. 6, pp. 9-17.

Kowatch et al., The Use of Mood Stabilizers and Atypical Antipsychotics in Children and Adolescents with Bipolar Disorders, CNS Spectrums, Apr. 2003, vol. 8, No. 4, pp. 273-280.

Shin Shiah et al., "Serotonin in Mania and in the Mechanism of Action of Mood Stabilizers: A Review of Clinical Studies", Bipolar Disorders: An International Journal of Psychiatry and Neurosciences; Dec. 24, 2001; Abstract; vol. 2, issue 2.

Bobula et al., "Adaptive Changes in the Reactivity of 5-HT_{1A} and 5-HT₂ Receptors Induced in Rat Frontal Cortex by Repeated Imipramine and Citalopram", Naunyn-Schmiedeberg's Arch Pharmacol, 2003, pp. 444-450, 367.

Ichikawa et al., "Valproate and Carbamazepine Increase Prefrontal Dopamine Release by 5-HT_{1A} Receptor Activation", European Journal of Pharmacology, 1999, pp. R1-R3, 367.

Brambilla et al., "Atypical Antipsychotics and Mood Stabilization in Bipolar Disorder", Psychopharmacologia, 2003, pp. 315-332, vol. 166 No. 4.

Robert M. Post et al., "Acute and prophylactic effects of anticonvulsants in bipolar depression", Clinical Neuroscience Research 2 (2002) 228-2511.

Yasuhiro Suzuki, "Zonisamide in West syndrome", Brain and development 23 (2001), 658-661.

English Translation of Egyptian Office Action dated Jun. 27, 2010.

Casey, Daniel, E., "Switching Patients to Aripiprazole From Other Antipsychotic Agents a Multicenter Randomized Study", Psychopharmacology (2003), 166, pp. 390-399.

* cited by examiner

FIG. 1




FIG. 2





FIG.3



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.